Post market surveillance of different brands of ofloxacin 200 mg tablets available in local market of Karachi (Pakistan)

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue SUPPL. 4, 2012, Pages 668-672

  Khalid, Samreen ^a   Gauhar, Shahnaz ^b   Rehman, Rabia ^c   Fatima, Sakina ^c  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b RAK MEDICAL AND HEALTH SCIENCES UNIVERSITY   (United Arab Emirates)

^c Department of Pharmaceutics   (India)

Author keywords

Biowaiver conditions; Dissolution testing; Ofloxacin; Quality control parameter; Similarity factor f2

Indexed keywords

OFLOXACIN;

ARTICLE; CRUSHING STRENGTH; DRUG SOLUBILITY; PAKISTAN; PH; POSTMARKETING SURVEILLANCE; TABLET DISINTEGRATION; TABLET HARDNESS; TABLET THICKNESS;

EID: 84866339624     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. "Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story". Clin Infect Dis. 2007; 44 (7): 977-80.
2. Kawahara, S. "Chemotherapeutic agents under study". Nippon Rinsho. 1998; 56 (12): 3096-9.
3. Sweetman SC (Ed), Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Electronic version, 35th Ed. 2007.
4. Drlica K, Zhao X. "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiol Mol Biol Rev. 1997; 61 (3): 377-92
5. Gennaro, A. R. Remington. The Science and Practice of Pharmacy. 20th edition. Easton Pennsylvania: Mack Publishing Company. 2000; 882-885.
6. Gennaro, A. R. Remington. The Science and Practice of Pharmacy. 19th edition. Easton Pennsylvania: Mack Publishing Company. 1995; 905-918
7. British Pharmacopoeia Volume I &II. British Pharmacopoeia commission. The stationery office limited, London; 2007; 249-267.
8. Ziyaur R, Mushir A, Khar RK. Design and Evaluation of bilayer floating tablets of captopril. Acta pharm., 2006; 56: 4957.
9. British Pharmacopoea Appendix: XII, Disintegration of tablets and capsules. Royal Publishers: London. 2002; H A2-53.
10. United States Pharmacopeia and National Formulary USP 32-NF 27. The United States Pharmacopeial Convention, Inc.: Rockville, MD., 2007; 1737.
11. United States Pharmacopeia and National Formulary USP 32-NF 27. The United States Pharmacopeial Convention, Inc.: Rockville, MD., 2007.
12. The United States Pharmacopeia 27. The United States Pharmacopeial Convention, Rockville, MD, USA, 2004; 2011-2012.
13. US FDA, Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1997.
14. Akinleye M Olusola, Oyetunde O Olubukola, Okpara H Emeka and Ayerota E Lilian. Equivalence of Two Generic Brands of Amlodipine Besylate under Biowaiver conditions. Int J Pharm Pharm Sci., 2012; 4 (2): 265-268
15. US Food and Drug Administration, Center for Drug Evaluation and Research Guidance for Industry-Waiver of InVivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
16. Raheela Bano, Shahnaz Gauhar, Syed Baqir Shyum Naqvi and Shoukat Mahmood "Pharmaceutical Evaluation of different brands of Levofloxacin tablets (250mg) available in local market of Karachi (Pakistan)". Int. J Curr Pharm Res., 2011; 3 (1):15-22